	US 11,988,672 B2
	CCL24 as a diagnostic and therapeutic target for breast cancer
Dev Karan, Cayce, SC (US); and Seema Dubey, Cayce, SC (US)
Assigned to University of South Carolina, Columbia, SC (US)
Filed by University of South Carolina, Columbia, SC (US)
Filed on Nov. 24, 2020, as Appl. No. 17/102,633.
Claims priority of provisional application 62/940,396, filed on Nov. 26, 2019.
Prior Publication US 2021/0208161 A1, Jul. 8, 2021
Int. Cl. G01N 33/68 (2006.01); C07K 16/24 (2006.01); G01N 33/50 (2006.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01)

CPC G01N 33/6863 (2013.01) [C07K 16/24 (2013.01); G01N 33/5044 (2013.01); G01N 33/5047 (2013.01); A61K 2039/505 (2013.01); C07K 2317/76 (2013.01); G01N 33/57415 (2013.01); G01N 2333/521 (2013.01)]

13 Claims

1. An immunohistochemistry method comprising:

examining a subject, via obtaining at least one breast cell tissue sample, to detect the presence of a tumor microenvironment;

employing immunohistochemistry staining of the at least one breast cell tissue sample to identify at least one cancer cell compartment in the at least one breast cell tissue sample;

measuring for a differential expression of CC Chemokine Ligand 24 (“CCL24”) in the tumor microenvironment of the at least one breast cell tissue sample to differentiate between at least one non-Triple Negative tumorigenic cell and at least one Triple Negative Breast Cancer cell;

measuring lymphocyte tracking events in the tumor microenvironment via gating at least one lymphocyte via employing at least one anti-CD45 antibody to analyze a level of at least one T-regulatory cell and at least one myeloid-derived suppressor cells; and

measuring the amount of CCL24 in the tumor microenvironment via multiplexed immunofluorescence to determine if the subject is positive for at least one Triple Negative Breast Cancer cell.